BioNTech posted a profit of more than € 1 billion in the first quarter

In the first quarter of this year, the German biotechnology research company BioNTech developed the first vaccine approved in the European Union by the American pharmaceutical giant Pfizer for the new type of Coronavirus disease (SARS-CoV-2) (Covid-19), it achieved more One billion euros in profit after tax.

The tech startup – the startup – launched in 2008, according to a report released Monday It generated a profit after tax of 1.128 billion euros, or 406 billion HUF In January-March, after a loss of 53.4 million euros a year ago.

The company reported a profit after tax of 1.128 billion euros, which is 406 billion HUF in the January-March periodSource: Agence France-Presse / Thomas Lonnes

Sales amounted to 2.048 billion euros, seventy times higher than the previous year of 27.7 million euros. The increase is attributed to demand for the vaccine against Covid-19, which is marketed under the brand name Comirnaty.

It was profitable for the first time last year

The product developed by Pfizer is the first BioNTech product by the beginning of May this year, about 450 million shares of customers have been delivered.

By the end of the year, there were secure orders for 1.8 billion payments, giving BioNTech € 12.4 billion in revenue. Additional orders are also expected to be produced, and three billion batches will be produced this year and more than three billion next year.

Originally specialized in developing agents to treat cancer, BioNTech over the first 12 years of its history has operated largely from venture capital and has consistently caused losses, and is commonplace in the biotech startup sector. Its main owner – with a stake of about 50 percent – is founders Thomas and Andreas Strongman. His German sister-in-law, one of the richest people in the world, made him a billionaire with the success of the pharmaceutical company Hexal.

In 2013, Catalin Kariku, a Hungarian researcher who became world famous for her Covid-19 vaccine, joined the company that employs about 1,500 people.

BioNTech co-founder Ugur Shaheen recently highlighted this at a press conference They made a profit for the first time last year – Profit after tax was 15.2 million after losing 180 million euros in 2019 – but this was not withdrawn from the company, but rather everything spent on development and research.

READ  Index - Abroad - Anyone who received a Chinese vaccine is also eligible to receive a third vaccine in the United Arab Emirates

Leave a Reply

Your email address will not be published. Required fields are marked *